Background Mantle cell lymphoma (MCL) is a distinct clinical pathologic subtype of B cell
non-Hodgkin's lymphoma often associated with poor prognosis. New therapeutic …

Mantle cell lymphoma (MCL) accounts for 5–10% of all non-Hodgkin lymphomas and has
the worst prognosis among all lymphomas. The hallmark of MCL is at (11; 14) translocation …

Cyclin D1 overexpression is the hallmark of mantle cell lymphoma (MCL). However, the
importance of cyclin D1 in the maintenance and progression of the disease remains to be …

Mantle cell lymphoma (MCL) 1 is characterized by dysregulated expression of cyclin D1 due
to the cytogenetic translocation t (11; 14)(q13; q32). 2 Cyclin D1 interaction with cyclin …

Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma with poor long-term overall
survival. Currently, MCL research and development of potential cures is hampered by the …

The prognosis for patients with mantle cell lymphoma (MCL) is poor, and at present there is
no truly effective therapy. Gene translocation-mediated constitutive expression of cyclin D1 …

Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell
lymphoma who, having achieved remission after immunochemotherapy, were vaccinated …

Cyclin D1 overexpression is believed to be essential in the pathogenesis of mantle cell
lymphoma (MCL). Hence, the existence of cyclin D1-negative MCL has been controversial …

Purpose: Mantle cell lymphoma (MCL) is characterized by the t (11; 14)(q13; q32)
translocation leading to cyclin D1 overexpression. Cyclin D1 is a major cell-cycle regulator …

Mantle cell lymphoma (MCL) is a distinct clinicopathologic entity of non-Hodgkin's
lymphoma, characterized by a monotonous proliferation of small to medium-sized …